154 related articles for article (PubMed ID: 37859733)
1. m6A reading protein RBMX as a biomarker for prognosis and tumor progression in esophageal cancer.
Tuersun H; Liu L; Zhang J; Maimaitizunong R; Tang X; Li H
Transl Cancer Res; 2023 Sep; 12(9):2319-2335. PubMed ID: 37859733
[TBL] [Abstract][Full Text] [Related]
2. Identification of clinical prognostic features of esophageal cancer based on m6A regulators.
Wang H; Zhang Y; Chen L; Liu Y; Xu C; Jiang D; Song Q; Wang H; Wang L; Lin Y; Chen Y; Chen J; Xu Y; Hou Y
Front Immunol; 2022; 13():950365. PubMed ID: 36159855
[TBL] [Abstract][Full Text] [Related]
3. High expression of caspase-8 as a predictive factor of poor prognosis in patients with esophageal cancer.
Chai J; Lei Y; Xiang X; Ye J; Zhao H; Yi L
Cancer Med; 2023 Mar; 12(6):7651-7666. PubMed ID: 36533709
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive Analysis of Hexokinase 2 Immune Infiltrates and m6A Related Genes in Human Esophageal Carcinoma.
Liu XS; Liu JM; Chen YJ; Li FY; Wu RM; Tan F; Zeng DB; Li W; Zhou H; Gao Y; Pei ZJ
Front Cell Dev Biol; 2021; 9():715883. PubMed ID: 34708035
[No Abstract] [Full Text] [Related]
5. Systematic investigation of the clinical significance and prognostic value of the CBXs in esophageal cancer.
Hou J; Yang Y; Gao H; Ouyang T; Liu Q; Ding R; Kan H
Medicine (Baltimore); 2022 Oct; 101(40):e30888. PubMed ID: 36221371
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive Analysis of GLUT1 Immune Infiltrates and ceRNA Network in Human Esophageal Carcinoma.
Liu XS; Gao Y; Wu LB; Wan HB; Yan P; Jin Y; Guo SB; Wang YL; Chen XQ; Zhou LM; Yang JW; Kui XY; Liu XY; Pei ZJ
Front Oncol; 2021; 11():665388. PubMed ID: 34123828
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive analysis of m6A related gene mutation characteristics and prognosis in colorectal cancer.
Jiang T; Xing L; Zhao L; Ye Z; Yu D; Lin S
BMC Med Genomics; 2023 May; 16(1):105. PubMed ID: 37194014
[TBL] [Abstract][Full Text] [Related]
8. APOC1 predicts a worse prognosis for esophageal squamous cell carcinoma and is associated with tumor immune infiltration during tumorigenesis.
Cao X; Wu B; Guo S; Zhong W; Zhu S; Zhang Z; Gu L; Li H
Pathol Oncol Res; 2023; 29():1610976. PubMed ID: 36969562
[No Abstract] [Full Text] [Related]
9. Bridging Integrator 3 (BIN3) Downregulation Predicts a Poor Prognosis in Patients with Esophagus Carcinoma: A Study based on TCGA Data.
Li D; Deng W; Huang G; Xiao X
Comb Chem High Throughput Screen; 2023; 26(11):1974-1989. PubMed ID: 36475339
[TBL] [Abstract][Full Text] [Related]
10. Identification and Validation of Chromobox Family Members as Potential Prognostic Biomarkers and Therapeutic Targets for Human Esophageal Cancer.
Fang X; Wang J; Chen J; Zhuang M; Huang T; Chen Z; Huang Y; Zheng B; Wang X
Front Genet; 2022; 13():851390. PubMed ID: 35464847
[No Abstract] [Full Text] [Related]
11. CSMD1 Mutation Related to Immunity Can Be Used as a Marker to Evaluate the Clinical Therapeutic Effect and Prognosis of Patients with Esophageal Cancer.
Fan X; Song J; Fan Y; Li J; Chen Y; Zhu H; Zhang Z
Int J Gen Med; 2021; 14():8689-8710. PubMed ID: 34849012
[TBL] [Abstract][Full Text] [Related]
12. Screening of potential key genes in esophageal cancer based on RBP and expression verification of HENMT1.
Reyimu A; Xing F; Zhou W; Zheng Y; Liu B; Dai J; Xing Y; Gao J
Medicine (Baltimore); 2023 Dec; 102(49):e36544. PubMed ID: 38065897
[TBL] [Abstract][Full Text] [Related]
13. RBMX suppresses tumorigenicity and progression of bladder cancer by interacting with the hnRNP A1 protein to regulate PKM alternative splicing.
Yan Q; Zeng P; Zhou X; Zhao X; Chen R; Qiao J; Feng L; Zhu Z; Zhang G; Chen C
Oncogene; 2021 Apr; 40(15):2635-2650. PubMed ID: 33564070
[TBL] [Abstract][Full Text] [Related]
14. Highly Expressed Z-DNA Binding Protein 1 in Esophageal Cancer Promotes Tumor Growth.
Wusiman S; Liu Y; Li H; Deng Y; Qu X; Tuerxun H; Liu L
Dig Dis Sci; 2024 May; 69(5):1674-1690. PubMed ID: 38507125
[TBL] [Abstract][Full Text] [Related]
15. Identification and validation of DPY30 as a prognostic biomarker and tumor immune microenvironment infiltration characterization in esophageal cancer.
Mei PY; Xiao H; Guo Q; Meng WY; Wang ML; Huang QF; Liao YD
Oncol Lett; 2023 Feb; 25(2):68. PubMed ID: 36644145
[TBL] [Abstract][Full Text] [Related]
16. Identification and validation of necroptosis-related prognostic gene signature and tumor immune microenvironment infiltration characterization in esophageal carcinoma.
Sun K; Hong JJ; Chen DM; Luo ZX; Li JZ
BMC Gastroenterol; 2022 Jul; 22(1):344. PubMed ID: 35840882
[TBL] [Abstract][Full Text] [Related]
17. Aberrant RBMX expression is relevant for cancer prognosis and immunotherapy response.
Sheng Y; Lei K; Sun C; Liu J; Tu Z; Zhu X; Huang K
Aging (Albany NY); 2024 Jan; 16(1):226-245. PubMed ID: 38214653
[TBL] [Abstract][Full Text] [Related]
18. Screening and verification of potential gene targets in esophageal carcinoma by bioinformatics analysis and immunohistochemistry.
Wen P; Dayyani F; Tao R; Zhong X
Ann Transl Med; 2022 Jan; 10(2):70. PubMed ID: 35282073
[TBL] [Abstract][Full Text] [Related]
19. Integrated Analysis of Hub Genes and Pathways In Esophageal Carcinoma Based on NCBI's Gene Expression Omnibus (GEO) Database: A Bioinformatics Analysis.
Yu-Jing T; Wen-Jing T; Biao T
Med Sci Monit; 2020 Aug; 26():e923934. PubMed ID: 32756534
[TBL] [Abstract][Full Text] [Related]
20.
Liu SP; Li XM; Liu DM; Xie SH; Zhang SB; Li Y; Xie ZF
Front Oncol; 2022; 12():884448. PubMed ID: 35530327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
